Surprise baby whale sightings along a busy 'humpback highway' prompt new worries
Surprise baby whale sightings along a busy 'humpback highway' prompt new worries Whale researchers have new data about humpback whales giving birth along a busy 'humpback highway' off Australia.
Show Caption
Hide Caption
Humpback whale almost swipes diver swimming with orcas
A diver, who was freediving with orcas, narrowly avoided being hit by the humpback's tail in Norway.
Whale researchers combined modern-day sightings with 19th century records and are revealing new information about when and where humpback whales give birth along a busy 'humpback highway' off Australia.
Humpback calves are being born not just in a calving zone at the end of the migration route, but along the way and even farther south than previously understood, according to a study led by researchers at the University of New South Wales.
That pattern raises new issues, including the need to increase awareness to protect newborn whales throughout their winter journeys, the authors wrote in the study published May 21 in the scientific journal Frontiers in Marine Science.
'Hundreds of humpback calves were born well outside the established breeding grounds,' said Tracey Rogers of the University of New South Wales, a senior author. 'Giving birth along the 'humpback highway' means these vulnerable calves, who are not yet strong swimmers, are required to swim long distances much earlier in life than if they were born in the breeding grounds.'
Newborn humpbacks aren't as strong as adult whales, and 'mums with newborns swim much more slowly,' Rogers said. 'Newborns are like Great Dane puppies. They have those long, enormous fins that they need to grow into, and they're not very strong swimmers. So they rest a lot of the time on their mum's back.'
Once near extinction, humpback whales have rebounded thanks to conservation programs. Today the population is estimated at roughly 50,000.
Sightings for the study were collected across an area extending from Queensland down to Tasmania and across to New Zealand's South Island.
'Historically, we believed that humpback whales migrating north from the nutrient-rich Southern Ocean were travelling to warmer, tropical waters such as the Great Barrier Reef to calve,' says lead author Jane McPhee-Frew, a PhD candidate at the University of New South Wales Sydney and whale watching skipper.
'The pattern we're seeing is mother whales with calves travelling through some of the busiest shipping lanes and urbanised regions," said McPhee-Frew. Her first calf sighting in Newcastle in 2023, home of the largest coal export port in the world, was within a busy shipping lane.
'This means these vulnerable animals are exposed to risks like boat strikes, entanglements, pollution – and just general public unawareness,' she said.
Questions remain about the whales' migration, including how the humpback mothers use different marine environments along their migration route and why they continue to travel north after giving birth, even though there's really no food for them in the tropics.
Dinah Voyles Pulver, a national correspondent for USA TODAY, covers climate change, wildlife and the environment. Reach her at dpulver@usatoday.com or @dinahvp on Bluesky or X or dinahvp.77 on Signal.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Miami Herald
a day ago
- Miami Herald
Portuguese man o' wars — known for their sting — are actually 4 species. See them
Despite their vibrant blue color and delicate bodies, seeing a Portuguese man o' war along the coast sends beachgoers in the opposite direction. These jellyfish-like animals are known instead for their sting, prompting warnings from wildlife officials when they make their way onto beaches around the world. Now, researchers studying these unique creatures have found that Portuguese man o' wars — also known as bluebottles — may actually belong to at least four distinct species. A research team led by Yale University, in Connecticut, and the University of New South Wales and Griffith University, in Australia, analyzed the genetics of more than 150 bluebottles from around the world to better understand how the widespread species was related to one another, according to a study published June 19 in the peer-reviewed journal Current Biology. The team sequenced the genome of each bluebottle, then grouped them together in clusters based on their geographic range in the oceans, according to the study. What they found was distinct genetic differences between groups of man o' wars from different areas, despite some overlap between the populations, according to the study. 'We were shocked, because we assumed they were all the same species,' study author Kylie Pitt said in a June 20 news release from Griffith University. 'But the genetic data clearly show they're not only different, they're not even interbreeding despite overlapping ranges. The bluebottle is uniquely suited to long-distance travel, using its gas-filled float and muscular crest to catch the wind and sail the sea surface.' The study describes four species: Physalia physalis, Physalia utriculus, Physalia megalista and Physalia minuta. Researchers confirmed the species deviations by comparing their collected man o' wars to more than 4,000 images posted on the citizen-science website iNaturalist, according to the study. They compared differences in tentacle length, color and other physical characteristics to previous records of man o' wars found around the world, including in centuries-old publications that previously argued the species should be broken up, according to the study. Physalia minuta is described for the very first time as a new species, according to the study. The species is 'distinguished from other Physalia by its small size at maturity and colony arrangement with multiple principle tentacles,' researchers said, earning the species its name 'minuta,' meaning small. The well-known Portuguese man o' war — Physalia physalis — may look like a jellyfish, but it's actually a siphonophore, or a colony of animals that live together to create the complete structure, according to the National Oceanic and Atmospheric Administration. The specialized animals are called zooids and are genetically identical but each serve a different function for survival, such as floating, catching prey or reproduction, NOAA says. Man o' wars use a balloon-like float to move up and down in the water column, according to NOAA, and their tentacles can grow an average of 30 feet long, with some man o' wars reaching as long as 100 feet. 'There's this idea the open oceans all connected, and it's just one species of bluebottle and they're all globally connected because they drift with the wind and the current. But that's absolutely not the case,' Pitt said in the release. 'And what's really interesting in Eastern Australia is that we have multiple species that have evolved despite potentially co-existing.' Researchers said further studies will be needed to understand why, despite overlapping and being in the same environment, the man o' wars deviated, according to the release. The research team includes Pitt, Samuel H. Church, River B. Abedon, Namrata Ahuja, Colin J. Anthony, Dalila Destanović, Diego A. Ramirez, Lourdes M. Rojas, Maria E. Albinsson, Itziar Álvarez Trasobares, Reza E. Bergemann, Ozren Bogdanovic, David R. Burdick, Tauana J. Cunha, Alejandro Damian-Serrano, Guillermo D'Elía, Kirstin B. Dion, Thomas K. Doyle, João M. Gonçalves, Alvaro Gonzalez Rajal, Steven H.D. Haddock, Rebecca R. Helm, Diane Le Gouvello, Zachary R. Lewis, Bruno I.M.M. Magalhães, Maciej K. Mańko, C. Gabriela Mayorga-Adame, Alex de Mendoza, Carlos J. Moura, Catriona Munro, Ronel Nel, Kohei Oguchi, Jessica N. Perelman, Laura Prieto, Moninya Roughan, Amandine Schaeffer, Andrea L. Schmidt, Javier Sellanes, Nerida G. Wilson, Gaku Yamamoto, Eric A. Lazo-Wasem, Chris Simon, Mary Beth Decker, Jenn M. Coughlan and Casey W. Dunn.
Yahoo
14-06-2025
- Yahoo
Scientists perplexed after discovering 'out of place' whales in unexpected location: 'What were they doing here?'
Research has found newborn humpback whales as far south as Tasmania, over 1,500 kilometers (932 miles) from where experts thought humpback mothers typically gave birth. According to The Guardian, the study began when Jane McPhee-Frew, whale-watching skipper and researcher at the University of New South Wales, spotted a tiny calf off Newcastle. "It seemed out of place," she told the publication. "The calf was tiny, obviously brand new. What were they doing here?" The previous understanding was that humpback mothers swam north to give birth in warmer, tropical waters near the Great Barrier Reef before heading south with their calves to feed in Antarctic waters. "It may be the case that this has always been happening and we've just not documented it well or been paying attention," said Dr. Vanessa Pirotta, the study's co-author and whale scientist, per The Guardian. "Or it may be something new is happening because waters are becoming warmer further south of those traditional tropical areas." Most of these unusual sightings have been recorded after 2016, indicating this could be a recent development. These unexpected whale births point to how much our oceans are changing. Australia's average sea surface temperatures have risen by 1.08°C since 1900, according to CSIRO data shared by The Guardian, with the highest rises recorded off southeast Australia and Tasmania. When marine animals change their behavior patterns dramatically, it can create new challenges for both the whales and the communities that share coastal waters with them. Baby whales in unexpected locations face more risks from ship strikes, fishing gear entanglement, and other human activities that weren't previously considered threats in these areas. Do you worry about air pollution in and around your home? Yes — always Yes — often Yes — sometimes No — never Click your choice to see results and speak your mind. "You've got human impacts — ship strike risks, entanglement risks, predation from natural predators, tourists and boats," Pirotta said about the navigation dangers along what researchers call the "humpback highway." The expanding range also means fishing communities, shipping companies, and coastal towns need to adjust their practices to account for whale mothers and calves in areas where they weren't previously expected. Scientists are working to understand and protect these whale families in their expanded range. Researchers like Dr. Angus Henderson from the University of Tasmania told The Guardian that speed restrictions and rerouting vessels away from whale habitat represent the most effective ways to minimize dangerous interactions. If you live near the coast, you can contribute by reporting any whale sightings to local marine research organizations. Boaters can help by maintaining safe distances from whales and reducing speeds in areas where mothers and calves might be present. Join our free newsletter for good news and useful tips, and don't miss this cool list of easy ways to help yourself while helping the planet.
Medscape
06-06-2025
- Medscape
Sibeprenlimab Halves uPCR in IgA Nephropathy Trial
VIENNA — Sibeprenlimab, a novel selective immune antibody, reduced the urine protein-to-creatinine ratio (uPCR) by more than half in patients with immunoglobulin A (IgA) nephropathy, according to an interim analysis of the VISIONARY trial. Beyond this clinical effect, a notable observation was the lack of safety concerns, especially given that, although sibeprenlimab is a selective agent, there may have been unexpected off-target effects. 'Safety's been a key consideration with these drugs,' study presenter Vlado Perkovic, MD, PhD, provost and scientia professor, University of New South Wales, Sydney, Australia, told Medscape Medical News . Sibeprenlimab represents a new mechanism of action and 'we don't yet fully understand the profile, so we've been looking at that data very carefully,' explained Perkovic. 'In particular, the infection risk has been my biggest concern, given we know that infections are dramatically increased in people with steroid therapy for example, in IgA nephropathy.' The results of the trial — the largest to date in the field — were presented at the 62nd European Renal Association Congress 2025 on June 6 and drew a warm applause from the audience. An Underestimated Condition IgA nephropathy is estimated to affect 2.5 per 100,000 people per year, although 'it's possible that that number is a significant underestimate,' said Perkovic. Diagnosis typically occurs between 20 and 40 years of age. And, despite supportive care, the majority of patients have a high lifetime risk of end-stage kidney disease (ESKD), with up to 50% of patients progressing to ESKD within 20 years of their clinical presentation. 'It's quite likely we've underestimated just how important this condition is,' said Perkovic, but 'we're fortunate that we're in the middle of something of a golden age of developing new treatments.' A number of therapies have been shown to reduce the risks associated with the disease, although they do not necessarily address the immunological basis of the condition. In addition to newer treatments, 'corticosteroids have long been used for people with IgA nephropathy,' Perkovic said, 'but of course, corticosteroids also have a range of different effects across the immune system,' which can lead to adverse outcomes. Sibeprenlimab is a selective IgG2 antibody that binds to and inhibits the biological activity of APRIL (a proliferation-inducing ligand), which is produced by mucosal epithelial and myeloid cells and binds to B cells. APRIL regulates B-cell-mediated immune responses and mediates IgG and IgA class switching in mature B cells. It is these two actions that make APRIL a key factor in the so-called 4-Hit process in the pathogenesis of IgA nephropathy, which results in the deposition of immune complexes in the glomerulus, leading to proteinuria and loss of kidney function. Phase 3 VISIONARY TRIAL Following on from the successful phase 2 ENVISION trial of sibeprenlimab, the researchers undertook the phase 3 VISIONARY trial, an ongoing study involving patients with biopsy-confirmed IgA nephropathy from 240 sites in 31 countries, who were randomized to sibeprenlimab or placebo for 100 weeks and followed up for a further 12 weeks. All patients were required to have a uPCR of ≥ 0.75 g/g or urine protein excretion of ≥ 1.0 g/day, an estimated glomerular filtration rate (eGFR) of ≥ 30 mL/min/1.73 m2, and to have been on a stable dose of either an angiotensin-converting enzyme inhibitor or angiotensin receptor blocker, with or without a SGLT2 inhibitor, for ≥ 3 months prior to screening. For the current pre-specified interim analysis, Perkovic reported the efficacy and safety results in the first 320 randomized patients (152 in the sibeprenlimab group and 168 in the placebo group), focusing on the primary endpoint of 24-hour uPCR at 9 months vs baseline, with eGFR and other data expected to be presented in 2026. The median age of the patients was 42-43 years. There were proportionally fewer females in the sibeprenlimab group (34.2%) vs the placebo group (40.5%). The majority of the patients were Asian, at 61.8% and 56.5%, respectively. Compared with a rise in uPCR at the 9-month follow-up in the placebo group, sibeprenlimab was associated with a 50.2% reduction in uPCR, giving a highly significant placebo-adjusted treatment effect of 51.2% ( P < .0001). Importantly, the benefit of sibeprenlimab on uPCR was seen as early as 4 weeks after initiating treatment and continued to accrue throughout follow-up. Ronald T. Gansevoort, MD, PhD, professor of medicine and a nephrologist at the Department of Nephrology, University Medical Center Groningen, Netherlands, who co-chaired the session, told Medscape Medical News that the results look 'very promising.' 'Recently, we have had several agents working in different ways that all show proteinuria lowering,' he continued, but the results from those studies show that the improvements seen in VISIONARY are 'the best proteinuria lowering' seen so far. Gansevoort noted, however, that this remains an interim analysis, and that he is really looking forward to seeing the kidney function results, adding: 'It was a little bit of a pity that they were not allowed to show at least the 9-month interim data on kidney function, which would have been so interesting.' Safety Results In terms of safety, the proportion of patients experiencing a treatment-related treatment-emergent adverse event (TEAE) was marginally lower with sibeprenlimab, at 32.9% vs 31.0% with placebo. The proportion of patients having a TEAE that led to treatment discontinuation was 0.7% vs 2.4%, respectively, and there were fewer severe and serious TEAEs with the experimental drug. 'If we focus on the infection-related adverse events,' Perkovic said, 'we can see that rates were numerically slightly higher in the sibeprenlimab than the placebo group, with a pattern that was broadly consistent, but with perhaps a slight excess of COVID 19.' He noted that this was 'the reverse of the pattern we've seen in the phase 2 trials, suggesting a chance' outcome. 'The data so far look remarkably encouraging,' he added. There's really no suggestion of an increased risk of infection,' with no opportunistic infections identified, 'and certainly no deaths.' More data is required from the ongoing follow-up to support what has been observed so far, but if the final results do bear out both the efficacy and safety outcome, it will show that sibeprenlimab is 'a precision approach to the fundamental abnormality in IgA nephropathy: that's the really exciting part,' said Perkovic. The study was funded by Otsuka Pharmaceutical Development and Commercialization. Perkovic declares relationships with Amgen, AstraZeneca, Bayer, Biogen, Boehringer Ingelheim, Chinook Therapeutics, Eli Lilly & Company, Gilead Sciences, GlaxoSmithKline, Guard Therapeutics, Incyte, Janssen, Merck, Mitsubishi Tanabe Pharma, Mundipharma, Novartis, Novo Nordisk, Otsuka, Pfizer, Roche, Sanofi, Shaanxi Micot Technology, Travere Therapeutics.
